Boston Scientific adjusts 2026 guidance, shares under pressure after Watchman target cuts

Boston Scientific trims its 2026 organic sales and EPS guidance amid slower Watchman growth, while Truist and other houses cut price targets but mostly keep positive ratings on the NYSE-listed medtech group.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 11:47.

Boston Scientific (US10117L1017) is back in focus on the NYSE after management cut its 2026 guidance and several research houses lowered price targets for the medtech stock. The changes come as growth in the Watchman heart device segment slows and the shares trade close to a fresh 52-week low.

What the guidance cut shows

According to a BioWorld report, CEO Mike Mahoney described 2026 as "more challenging" and reduced Boston Scientific's organic sales growth guidance to 6.5% to 8%, down from a previous 10% to 11% range. The company also lowered its adjusted earnings-per-share guidance to 3.34 to 3.41 dollars from 3.43 to 3.49 dollars, giving analysts room to reset expectations after a sharp share-price decline. BioWorld’s coverage of the 2026 guidance update

Analysts pare back Watchman optimism

Pressure on the stock is closely tied to the Watchman left-atrial appendage closure device, where Truist cut its Boston Scientific price target from 85 to 64 dollars on June 4 while maintaining a Buy rating, citing weaker-than-expected demand trends. The Truist note highlighted that Watchman sales in Q4 2025 came in about 1 percent below analyst expectations and that doctors increasingly bundle Watchman procedures with other cardiac interventions, flattening procedure volumes in the near term. Truist’s price-target cut and Watchman commentary

How the stock trades after the reset

Investing.com reports that Boston Scientific shares recently touched a 52-week low around 44.41 dollars, a marked drop from a high of roughly 109.50 dollars in the same period, corresponding to a one-year change of about minus 56.6 percent. The article notes that despite the decline, the group still trades on a price-to-earnings ratio near 18.6 and is regarded by some services as being in oversold territory, giving longer-term investors a data point for valuation discussions. Investing.com snapshot on the 52-week low

The product behind the stock

Boston Scientific generates revenue primarily from minimally invasive medical devices used in cardiology, endoscopy and neuromodulation, with the Watchman left-atrial appendage closure system representing a key flagship product in structural heart therapies. The Watchman device is designed to reduce stroke risk in certain atrial fibrillation patients by sealing the left-atrial appendage, and its procedure volumes and pricing play a central role in current guidance and analyst debates.

Where the shares trade today

Boston Scientific shares (US10117L1017) trade on the NYSE under the ticker BSX; as of 2026-06-23, 11:30 New York time, they change hands around 44.50 US dollars according to recent quote data.

Key data on the Boston Scientific shares

• Company: Boston Scientific Corporation
• ISIN: US10117L1017
• WKN: 884113
• Ticker: BSX
• Trading venue: NYSE
• Price (as of 2026-06-23, 11:30): 44.50 USD
• Market cap: approximately 32 billion USD (as of 2026-06-23)
• Sector / industry: Health Care, Medical Devices
• Index membership: S&P 500
• Next earnings date: 2026-07-24

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. Figures and dates are based on sources cited and may be updated by the company or exchanges without notice.